JHJiliang Hu

Jiliang Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiliang Hu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Baojin Zhai

    Stroke Center, The Affiliated Shenzhen Nanshan Hospital, Guangdong Medical College, Shenzhen, Guangdong, China

    1 shared publication
  • Dong Chen

    Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China

    1 shared publication
  • Fei Yan

    State Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China

    1 shared publication
  • Hao Wang

    Department of Neurosurgery, Shenzhen People's Hospital, Second Clinical Medical College of Jinan University, Shenzhen, China

    1 shared publication
  • Hao Wang

    Department of Laboratory Medicine Zhongshan Hospital Fudan University Shanghai China

    1 shared publication
  • Hao Wang

    Prenatal Diagnosis Center , Hangzhou Women’s Hospital , Hanghzou , China

    1 shared publication

Latest Publications

  • Medical Image Analysis and Health Informatics Evaluation of Bevacizumab Targeted Treatment in Severe Brain Edema

    by Hao Wang, Shen Hu, Dong Chen, Jiliang Hu

    Objective: Severe brain edema is one of the most difficult problems of nervous system disease and trauma. The study evaluates the clinical application and value of bevacizumab targeted treatment in severe cerebral edema using medical image analysis and health informatics. Methods: A retrospective study was performed on 29 patients with severe cerebral edema underwent bevacizumab targeted therapy in Nanshan Hospital of Guang dong Medical University from March 2014 to January 2016. Health information like the dynamic head MRI, namely MRI image analysis, and Glass Coma Scale (GCS) score were used to evaluate patients 3 weeks after surgery, the subsequently modified Rankin scale was used to evaluate the quality of life of patients, 6 months after treatment. Results: Bevacizumab reversed the brain edema damage, general markedly effective time at the first week after treatment, in 2–3 weeks sustained significant effect. The degree of cerebral edema was significantly reduced 3 weeks after treatment, the range of edema was significantly reduced, GCS score was significantly higher than pre-treatment, and the modified Rankin scale score reduced significantly compared with pre-treatment, all of which had statistical significance (P < 0.01). Conclusion: Preliminary evaluation of bevacizumab targeted treatment in severe cerebral edema can significantly promote the brain edema subsided, reverse lesion and improve overall clinical outcome.


  • Increased concentration of serum periostin is associated with poor outcome of patients with aneurysmal subarachnoid hemorrhage

    by Weijian Luo, Hao Wang, Jiliang Hu

    Objective: To explore the role of serum periostin in patients with aneurysmal subarachnoid hemorrhage (aSAH).Method: We conducted a retrospective study and 124 aSAH patients treated in Shenzhen People's hospital during March 1st 2015 to December 30th 2016 were included. Baseline information, neurological status and clinical outcome were recorded. Blood samples on admission were collected and enzyme linked immunosorbent assay (ELISA) kits were used to detect the serum level of periostin. Spearman's Correlation Analysis was used to analyze the correlation between periostin and clinical severity. Receiver operating characteristic (ROC) curve was performed to investigate variables’ prognostic value in patients with aSAH.Results: The average age of patients included was 57.23 years old. Preliminary analysis revealed that serum periostin was significantly correlated with clinical severity. Patients with poor outcome at 12 months had higher level of periostin than patients with good outcome. Multivariate logistic regression analysis showed elevated level of periostin was significantly associated with poor outcome and the AUC was 0.85 for periostin in predicting poor outcome of patient with aSAH.Conclusion: Elevated serum periostin concentrations are significantly associated with clinical severity and poor outcome of aSAH patients, which indicate serum periostin can be used as a prognostic biomarker in patients with aSAH.


  • Open Access

    Tumor Restrictive Suicide Gene Therapy for Glioma Controlled by the FOS Promoter

    by Jianqing Pan, Hao Wang, Xinmin Liu, Jiliang Hu, Weijian Song, Jie Luo, Shan Jiang, Fei Yan, Baojin Zhai

    Effective suicide gene delivery and expression are crucial to achieving successful effects in gene therapy. An ideal tumor-specific promoter expresses therapeutic genes in tumor cells with minimal normal tissue expression. We compared the activity of the FOS (FBJ murine osteosarcoma viral oncogene homolog) promoter with five alternative tumor-specific promoters in glioma cells and non-malignant astrocytes. The FOS promoter caused significantly higher transcriptional activity in glioma cell lines than all alternative promoters with the exception of CMV. The FOS promoter showed 13.9%, 32.4%, and 70.8% of the transcriptional activity of CMV in three glioma cell lines (U87, U251, and U373). Importantly, however, the FOS promoter showed only 1.6% of the transcriptional activity of CMV in normal astrocytes. We also tested the biologic activity of recombinant adenovirus containing the suicide gene herpes simplex virus thymidine kinase (HSV-tk) driven by the FOS promoter, including selective killing efficacy in vitro and tumor inhibition rate in vivo. Adenoviral-mediated delivery of the HSV-tk gene controlled by the FOS promoter conferred a cytotoxic effect on human glioma cells in vitro and in vivo. This study suggests that use of the FOS-tk adenovirus system is a promising strategy for glioma-specific gene therapy but still much left for improvement.